Hot Topics for Drug Discovery: Finding the Next Lead was a one day meeting held at SCI HQ, London and organised by SCI’s Fine Chemicals Group.
This meeting focused on the highlights of drug discovery, the changes and some best practices seen in the industry. The aim of this symposium was to address what has changed in the drug discovery process over the last decade. Speakers highlighted what has been learned, which strategies have born the fruit they promised and which have been adopted as best practice as well as those which have fallen by the wayside. The symposium represented an ideal opportunity to hear and challenge opinions from the major players in the field through speakers accounts of their experiences and case studies. There was an excellent line-up of speakers from large and medium sized companies covering, a wide range of hot topics and approaches applied to the drug discovery process.
Overview of last 10 years: Success and failures
Andy Bell, Pfizer, Sandwich, UK
Target validation and drugability
James Mills, Pfizer, Sandwich, UK
- Applying intelligence upfront to screening campaigns: Compound selection and focused library design
Martin John Slater, BioFocus DPI, Essex, UK
- Case study: The identification of a novel structural class of ENaC blockers by high-throughput screening
Catherine Howsham, Novartis, UK
Case study: HTS and non-HTS approaches towards TRPV1 antagonists
Ronnie Palin, Schering-Plough Corporation, Motherwell, UK
- Encoded library Technology: A new approach to lead discovery
Barry Morgan, GlaxoSmithKline, MA, USA
The use of target immobilised NMR screening to identify and develop fragment binders for Hsp90
John Porter, UCB Pharma, Slough, UK
- The future of lead generation
John Steele, AstraZeneca R&D, Mölndal, Sweden
We are unable to make all presentations available due to copyright issues.
- "First SCI event I’ve attended and it was very good"
© 2009 Society of Chemical Industry (SCI).
All rights reserved.